Association of elevated rotavirus-specific antibody titers with HBGA secretor status in Swedish individuals: The FUT2 gene as a putative susceptibility determinant for infection

Virus Research

Volumn 211, Issue , 2016, Pages 64-68

  Günaydin, Gökçe ^a   Nordgren, Johan ^b   Sharma, Sumit ^b   Hammarstrom, Lennart ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antibody response; FUT2; Histo blood group antigen (HBGA); Lewis; Rotavirus; Secretor

Indexed keywords

BLOOD GROUP ANTIGEN; HISTO BLOOD GROUP ANTIGEN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; 3-GALACTOSYL-N-ACETYLGLUCOSAMINIDE 4-ALPHA-L-FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE; GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUT2 GENE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SWEDEN; SWEDISH CITIZEN; VIRUS MUTATION; VIRUS STRAIN; ADULT; BLOOD; CLASSIFICATION; DISEASE PREDISPOSITION; FEMALE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; ROTAVIRUS; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; BLOOD GROUP ANTIGENS; DISEASE SUSCEPTIBILITY; FEMALE; FUCOSYLTRANSFERASES; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; ROTAVIRUS; ROTAVIRUS INFECTIONS; SWEDEN;

EID: 84951741285     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2015.10.005     Document Type: Article

References (35)

1. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., Binka F.N., Steele A.D., Laserson K.F., Ansah N.A., Levine M.M., Lewis K., Coia M.L., Attah-Poku M., Ojwando J., Rivers S.B., Victor J.C., Nyambane G., Hodgson A., Schödel F., Ciarlet M., Neuzil K.M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 9741:606-614.
2. Borén T., Falk P., Roth K.A., Larson G., Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993, 262:1892-1895.
3. Desselberger U., Huppertz H.I. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J. Infect. Dis. 2011, 203:188-195.
4. Elmgren A., Mollicone R., Costache M., Börjeson C., Oriol R., Harrington J., Larson G. Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII. J. Biol. Chem. 1997, 272:21994-21998.
5. Esona M.D., Steele D., Kerin T., Armah G., Peenze I., Geyer A., Page N., Nyangao J., Agbaya V.A., Trabelsi A., Tsion B., Aminu M., Sebunya T., Dewar J., Glass R., Gentsch J. Determination of the G and P types of previously nontypeable rotavirus strains from the African Rotavirus Network, 1996-2004: identification of unusual G types. J. Infect. Dis. 2010, 202(Suppl):S49-S54.
6. Franco M.A., Angel J., Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731.
7. Greenberg H., McAuliffe V., Valdesuso J., Wyatt R., Flores J., Kalica A., Hoshino Y., Singh N. Serological analysis of the subgroup protein of rotavirus, using monoclonal antibodies. Infect. Immun. 1983, 39:91-99.
8. Hu L., Crawford S.E., Czako R., Cortes-Penfield N.W., Smith D.F., Le Pendu J., Estes M.K., Prasad B.V. Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature 2012, 485:256-259.
9. Huang P., Xia M., Tan M., Zhong W., Wei C., Wang L., Morrow A., Jiang X. Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J. Virol. 2012, 86:4833-4843.
10. Imbert-Marcille B.M., Barbé L., Dupé M., Le Moullac-Vaidye B., Besse B., Peltier C., Ruvoën-Clouet N., Le Pendu J., et al. A FUT2 gene common polymorphism determines resistance to rotavirus A of the P[8] genotype. J. Infect. Dis. 2014, 209:1227-1230.
11. Istrate C., Hinkula J., Hammarström L., Svensson L. Individuals with selective IgA deficiency resolve rotavirus disease and develop higher antibody titers (IgG, IgG1) than IgA competent individuals. J. Med. Virol. 2008, 80:531-535.
12. Larsson M.M., Rydell G.E., Grahn A., Rodriguez-Diaz J., Akerlind B., Hutson A.M., Estes M.K., Larson G., Svensson L. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J. Infect. Dis. 2006, 194:1422-1427.
13. Liu Y., Huang P., Tan M., Liu Y., Biesiada J., Meller J., Castello A.A., Jiang B., Jiang X. Rotavirus VP8*: phylogeny, host range, and interaction with histo-blood group antigens. J. Virol. 2012, 86:9899-9910.
14. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., Ngwira B., Victor J.C., Gillard P.H., Cheuvart B.B., Han H.H., Neuzil K.M. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 2010, 4:289-298.
15. Marionneau S., Cailleau-Thomas A., Rocher J., Le Moullac-Vaidye B., Ruvoën N., Clément M., Le Pendu J. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 2001, 83:565-573.
16. Nilsson M., Sigstam G., Svensson L. Antibody prevalence and specificity to group C rotavirus in Swedish sera. J. Med. Virol. 2000, 60:210-215.
17. Nordgren J., Sharma S., Bucardo F., Nasir W., Gunaydin G., Ouermi D., Nitiema L.W., Becker-Dreps S., Simpore J., Hammarstrom L., Larson G., Svensson L. Both lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin. Infect. Dis. 2014, 11:1567-1573.
18. Nordgren J., Nitiema L.W., Ouermi D., Simpore J., Svensson L. Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS One 2013, 8:e69557.
19. Parmar A.S., Alakulppi N., Paavola-Sakki P., Kurppa K., Halme L., Färkkilä M., Turunen U., Lappalainen M., Kontula K., Kaukinen K., Mäki M., Lindfors K., Partanen J., Sistonen P., Mättö J., Wacklin P., Saavalainen P., Einarsdottir E. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. Tissue Antigens 2012, 80:488-493.
20. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J. Infect. Dis. 2009, 200(Suppl. 1):S39-S48.
21. Reid M.E., Lomas-Francis C., Olssons M.L. The Blood Group Antigen Factsbook 2012, Elsevier. third ed.
22. Ruggeri F.M., Johansen K., Basile G., Kraehenbuhl J.P., Svensson L. Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J. Virol. 1998, 72:2708-2714.
23. Rydell G.E., Kindberg E., Larson G., Svensson L. Susceptibility to winter vomiting disease: a sweet matter. Rev. Med. Virol. 2011, 21:370-382.
24. Santos N., Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 2005, 15:29-56.
25. Soejima M., Munkhtulga L., Iwamoto S., Koda Y. Genetic variation of FUT3 in Ghanaians, Caucasians, and Mongolians. Transfusion (Paris) 2009, 49:959-966.
26. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., Network W-cGRS 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2008, 12:136-141.
27. Taylor-Cousar J.L., Zariwala M.A., Burch L.H., Pace R.G., Drumm M.L., Calloway H., Fan H., Weston B.W., Wright F.A., Knowles M.R., Group G.M.S. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One 2009, 4:e4270.
28. Van Trang N., Vu H.T., Le N.T., Huang P., Jiang X., Anh D.D. Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children. J. Clin. Microbiol. 2014, 5:1366-1374.
29. Velázquez F.R. Protective effects of natural rotavirus infection. Pediatr. Infect. Dis. J. 2009, 28:S54-S56.
30. Vildevall M., Grahn A., Oliver S.L., Bridger J.C., Charpilienne A., Poncet D., Larson G., Svensson L. Human antibody responses to bovine (Newbury-2) norovirus (GIII.2) and association to histo-blood group antigens. J. Med. Virol. 2010, 82:1241-1246.
31. Wacklin P., Tuimala J., Nikkilä J., Sebastian Tims, Mäkivuokko H., Alakulppi N., Laine P., Rajilic-Stojanovic M., Paulin L., de Vos W.M., Mättö J. Faecal microbiota composition in adults is associated with the FUT2 gene determining the secretor status. PLoS One 2014, 9:e94863.
32. Wang N., Hammarstrom L. IgA deficiency: what is new?. Curr. Opin. Allergy Clin. Immunol. 2012, 12:602-608.
33. WHO, 2013. Rotavirus Vaccines WHO Position Paper: January 2013-Recommendations, vol 52, p 6170-6171. Vaccine.
34. WHO, 2011. Global Rotavirus Information and Surveillance Bulletin. Reporting period: January through December 2010 vol 4.
35. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., Podder G., Vu D.T., Le T.P., Luby S.P., Le H.T., Coia M.L., Lewis K., Rivers S.B., Sack D.A., Schödel F., Steele A.D., Neuzil K.M., Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 9741:615-623.